دورية أكاديمية
أعرض في EDS

Antibiotic Use Prior to COVID-19 Vaccine Is Associated with Higher Risk of COVID-19 and Adverse Outcomes: A Propensity-Scored Matched Territory-Wide Cohort

التفاصيل البيبلوغرافية
العنوان: Antibiotic Use Prior to COVID-19 Vaccine Is Associated with Higher Risk of COVID-19 and Adverse Outcomes: A Propensity-Scored Matched Territory-Wide Cohort
المؤلفون: Ka Shing Cheung, Vincent K. C. Yan, Lok Ka Lam, Xuxiao Ye, Ivan F. N. Hung, Esther W. Chan, Wai K. Leung
المصدر: Vaccines, Vol 11, Iss 8, p 1341 (2023)
بيانات النشر: MDPI AG, 2023.
سنة النشر: 2023
المجموعة: LCC:Medicine
مصطلحات موضوعية: antibiotic, COVID-19 vaccine, adverse outcomes, Medicine
الوصف: Background: Antibiotics may increase the risk of COVID-19 among non-vaccinated subjects via probable gut dysbiosis. We aimed to investigate whether antibiotics also affect the clinical outcomes of COVID-19 vaccine recipients. Methods: This was a territory-wide cohort study of 3,821,302 COVID-19 vaccine recipients (aged ≥ 18 years) with ≥2 doses of either BNT162b2 or CoronaVac. Exclusion criteria included prior COVID-19, prior gastrointestinal surgery, and immunocompromised status. The primary outcome was COVID-19 infection and secondary outcomes included COVID-19-related hospitalization and severe infection (composite of intensive care unit admission, ventilatory support, and/or death). Exposure was pre-vaccination antibiotic use (within 180 days of first vaccine dose). Covariates included age, sex, Charlson Comorbidity Index, and concomitant medication use. Subjects were followed from the index date (first dose vaccination) until outcome occurrence, death, an additional dose of vaccination, or 15 November 2022. Propensity score (PS) matching and a Poisson regression model were used to estimate the adjusted incidence rate ratio (aIRR) of outcomes with antibiotic use. Results: Among 342,338 PS matched three-dose vaccine recipients (mean age: 57.4 years; male: 45.1%) with a median follow-up of 13.6 months (IQR: 9.2–16.3), antibiotics were associated with a higher risk of COVID-19 infection (aIRR: 1.16;95% CI: 1.14–1.19), hospitalization (aIRR: 1.75;95% CI: 1.65–1.86), and severe infection (aIRR: 1.60; 95% CI: 1.21–2.11). Notably, antibiotic use was associated with a higher risk of severe infection and death among CoronaVac recipients (aIRR: 1.62 95% CI: 1.18–2.22 and aIRR: 2.70, 95% CI: 1.54–4.73 for the two secondary outcomes, respectively), but not BNT162b2 recipients. Conclusions: Pre-vaccination use of antibiotics was associated with a higher risk of COVID-19 infection, hospitalization, and severe disease outcomes.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 11081341
2076-393X
Relation: https://www.mdpi.com/2076-393X/11/8/1341; https://doaj.org/toc/2076-393X
DOI: 10.3390/vaccines11081341
URL الوصول: https://doaj.org/article/213eeb1401f24286b1ad313ab4f54d1a
رقم الأكسشن: edsdoj.213eeb1401f24286b1ad313ab4f54d1a
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:11081341
2076393X
DOI:10.3390/vaccines11081341